Lundbeck to Cut 600 Sales Jobs in Europe on Drug Lineup
Reorganization costs may total as much as 500 million kroner ($85 million) this year, the Copenhagen-based company said in a statement today. The job cuts will affect sales personnel who work with general practitioners, said Mads Kronborg, a spokesman.
Lundbeck expects European approval of its alcoholism treatment nalmefene by the end of 2012. It’s also planning to submit a new antidepressant, known as LU AA21004, for regulatory clearance in the U.S. and Europe later this year.
To contact the reporter on this story: Makiko Kitamura in London at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.